BIOLINERX LTD/S (BLRX) Stock Rating Upgraded by Zacks Investment Research
Zacks Investment Research upgraded shares of BIOLINERX LTD/S (NASDAQ:BLRX) from a hold rating to a buy rating in a research note published on Friday morning, Zacks.com reports. They currently have $0.50 price objective on the biotechnology company’s stock.
According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “
Several other research firms have also recently issued reports on BLRX. Oppenheimer reaffirmed a buy rating on shares of BIOLINERX LTD/S in a research report on Tuesday, March 19th. HC Wainwright set a $3.00 price objective on shares of BIOLINERX LTD/S and gave the stock a buy rating in a research report on Thursday, March 28th. Finally, Maxim Group set a $2.00 price objective on shares of BIOLINERX LTD/S and gave the stock a buy rating in a research report on Thursday, March 28th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. BIOLINERX LTD/S presently has an average rating of Buy and an average target price of $2.13.
BIOLINERX LTD/S (NASDAQ:BLRX) last released its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.05). As a group, sell-side analysts forecast that BIOLINERX LTD/S will post -0.17 earnings per share for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in BLRX. ETF Managers Group LLC lifted its position in BIOLINERX LTD/S by 79.4% in the fourth quarter. ETF Managers Group LLC now owns 375,909 shares of the biotechnology company’s stock valued at $164,000 after acquiring an additional 166,386 shares during the last quarter. Menta Capital LLC purchased a new stake in BIOLINERX LTD/S in the fourth quarter valued at $33,000. Two Sigma Securities LLC purchased a new stake in BIOLINERX LTD/S in the fourth quarter valued at $25,000. Deutsche Bank AG purchased a new stake in BIOLINERX LTD/S in the fourth quarter valued at $26,000. Finally, Delek Group Ltd. purchased a new stake in BIOLINERX LTD/S in the first quarter valued at $92,000. 33.72% of the stock is owned by hedge funds and other institutional investors.
About BIOLINERX LTD/S
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Recommended Story: What Is An Exchange-Traded Fund (ETF)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.